April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Function And Phenotype In The Natural History Of Type 2 Idiopathic Macular Telangiectasia
Author Affiliations & Notes
  • Ferenc B. Sallo
    Research & Development,
    Moorfields Eye Hospital, London, United Kingdom
  • Tunde Peto
    Research & Development,
    Moorfields Eye Hospital, London, United Kingdom
  • Emily Y. Chew
    Epidemiology & Clinical Applications, National Eye Inst/NIH, Bethesda, Maryland
  • Alan C. Bird
    Inherited Eye Disease,
    Moorfields Eye Hospital, London, United Kingdom
  • Traci E. Clemons
    Statistics, Emmes Corporation, Rockville, Maryland
  • MacTel Study Group
    Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  Ferenc B. Sallo, None; Tunde Peto, None; Emily Y. Chew, None; Alan C. Bird, None; Traci E. Clemons, None
  • Footnotes
    Support  The Lowy Medical Foundation, NIHR BMRC for Ophthalmology
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4523. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ferenc B. Sallo, Tunde Peto, Emily Y. Chew, Alan C. Bird, Traci E. Clemons, MacTel Study Group; Function And Phenotype In The Natural History Of Type 2 Idiopathic Macular Telangiectasia. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4523.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

The clinical features of type 2 Idiopathic Macular Telangiectasia (MacTel) include neurodegenerative changes such as inner and outer retinal cavities or a break in the photoreceptor inner-outer segment (IS/OS) junction line and vascular abnormalities including late-stage fluorescein leakage. Our aim was to compare progression in the phenotype of the disease with change in central visual function.

 
Methods:
 

Patients were selected from the MacTel study, an international multi-centre prospective study of type 2 MacTel. Fluorescein angiographic (FA) images of eyes with leakage in a maximum of one subfield of the grading grid at baseline were graded for extent and level of leakage. An increase by at least two subfields was considered significant. Stratus OCT scans were graded for the presence and location of retinal cavities and/or an IS/OS break. Grading was performed according to the MacTel Study protocol and correlated with best-corrected visual acuities (BCVA).

 
Results:
 

Mean loss in VA associated with a significant progression in fluorescein leakage (34 of 147 eyes), was 4.7±1.8 letters (95% CI: 1.2 - 8.2) after one year, and in 18 eyes a further 3.0±2.4 letters (95% CI: -1.7 - 7.8) after 2 years. The development of inner cavities involving the foveal centre (23 of 119 eyes) was associated with a mean VA loss of 4.7±1.9 letters (95% CI: 1.0 - 8.3) after one year and in 9 eyes (39%) a further 3.1±1.9 letters (95% CI: -0.5 - 6.8) after 2 years. At 2 years 10% of these eyes lost 13+ letters. The progression of an IS/OS break to involve the fovea (276 eyes) was associated in 37 eyes (13%) with a mean VA loss of 6.3±1.7 letters (95% CI: 3.0 - 9.6) after one year, 29 eyes (78%) progressed by 2 years with a further loss of 8.2±5.8 letters (95% CI: -3.2 - 19.7) letters.

 
Conclusions:
 

The retinal abnormalities examined were variable but in combination useful predictors of BCVA loss. Further analyses are necessary to determine risk factors for developing vision loss of 10+ letters. Establishing the sequence, time course and functional significance of retinal changes in MacTel is essential for developing a new classification system for describing the natural history and predicting the progression of the disease.

 
Keywords: retinal degenerations: hereditary • macula/fovea • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×